Pacira BioSciences Lowers FY2026 Sales Guidance from $745.000M-$770.000M to $735.000M-$760.000M vs $766.384M Est

Benzinga Newsdesk www.benzinga.com Negative 96.3%

Neg 96.3% Neu 0% Pos 0%

Pacira BioSciences (NASDAQ:PCRX) lowers FY2026 sales outlook from $745.000 million-$770.000 million to $735.000 million-$760.000 million vs $766.384 million estimate.